ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Clinical trials for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Cure leukemia
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs work by blocking different signals that …
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug gilteritinib may beat standard therapy in preventing AML relapse after transplant
Disease control Recruiting nowThis Phase 3 trial tests whether the drug gilteritinib is better than sorafenib at keeping leukemia from coming back in patients with a specific gene mutation (FLT3-ITD) after a stem cell transplant. About 594 adults and teens will take one of the two pills daily for up to 2 year…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New drug cocktail may replace bone marrow transplant for some leukemia patients
Disease control Recruiting nowThis study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo tackles Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests a combination of two drugs, vyxeos and gilteritinib, for adults whose FLT3-mutated acute myeloid leukemia has come back or not responded to prior treatment. The goal is to find the safest dose and see how many patients achieve remission. Participants …
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New leukemia drug candidate undergoes heart safety check
Knowledge-focused Recruiting nowThis early-stage trial is testing whether a single dose of XY0206 tablets affects the heart's electrical activity (QTc interval) in 45 healthy Chinese adults. Participants are randomly assigned to receive XY0206, a placebo, or an active control (moxifloxacin). The study lasts 3 d…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:01 UTC